Denali Therapeutics, Royalty Pharma announce $275 mln funding agreement

• Denali Therapeutics and Royalty Pharma announce $275 million royalty funding agreement. • Agreement based on future net sales of tividenofusp alfa. • Tividenofusp alfa is Denali's lead investigational treatment for mucopolysaccharidosis type II. • Biologics License Application for accelerated approval under review by FDA. • Prescription Drug User Fee Act target date is April 5, 2026. • Partnership recognizes value and potential of tividenofusp alfa. • Funding will support Denali's ongoing research and development efforts.